Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study.

Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM.

Lancet. 2011 Jun 18;377(9783):2085-92. doi: 10.1016/S0140-6736(11)60551-5.

PMID:
21684381
2.

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G; HPV PATRICIA Study Group..

Lancet Oncol. 2012 Jan;13(1):89-99. doi: 10.1016/S1470-2045(11)70286-8. Erratum in: Lancet Oncol. 2012 Jan;13(1):e1.

PMID:
22075171
3.

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.

Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM.

BMC Med. 2013 Oct 22;11:227. doi: 10.1186/1741-7015-11-227.

4.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534.

PMID:
20139221
5.

HPV vaccine effect: is the glass half full or half empty?

Saraiya M, Hariri S.

Lancet. 2011 Jun 18;377(9783):2057-8. doi: 10.1016/S0140-6736(11)60650-8. No abstract available. Erratum in: Lancet. 2011 Aug 27;378(9793):770.

PMID:
21684367
6.

Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women.

Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK.

J Natl Cancer Inst. 2014 Mar;106(3):djt460. doi: 10.1093/jnci/djt460.

PMID:
24552678
7.

The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.

Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH.

J Med Econ. 2010 Mar;13(1):110-8. doi: 10.3111/13696990903546013.

PMID:
20085477
8.

Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study).

Young EJ, Tabrizi SN, Brotherton JM, Wark JD, Pyman J, Saville M, Wrede CD, Jayasinghe Y, Tan J, Gertig DM, Pitts M, Garland SM.

BMC Cancer. 2013 Jun 19;13:296. doi: 10.1186/1471-2407-13-296.

9.

Cytology and cervical cancer surveillance in an era of human papillomavirus vaccination.

Budd AC, Sturrock CJ.

Sex Health. 2010 Sep;7(3):328-34. doi: 10.1071/SH09133.

PMID:
20719223
10.

Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.

Ogilvie GS, Naus M, Money DM, Dobson SR, Miller D, Krajden M, van Niekerk DJ, Coldman AJ.

Int J Cancer. 2015 Oct 15;137(8):1931-7. doi: 10.1002/ijc.29508.

11.

Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand.

Simonella LM, Lewis H, Smith M, Neal H, Bromhead C, Canfell K.

BMC Infect Dis. 2013 Mar 3;13:114. doi: 10.1186/1471-2334-13-114.

12.

Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program.

Baldur-Felskov B, Dehlendorff C, Junge J, Munk C, Kjaer SK.

Cancer Causes Control. 2014 Jul;25(7):915-22. doi: 10.1007/s10552-014-0392-4.

PMID:
24797870
13.

Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.

Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M.

J Natl Cancer Inst. 2012 Nov 21;104(22):1712-23. doi: 10.1093/jnci/djs395.

PMID:
23104323
14.

Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada.

Mahmud SM, Kliewer EV, Lambert P, Bozat-Emre S, Demers AA.

J Clin Oncol. 2014 Feb 10;32(5):438-43. doi: 10.1200/JCO.2013.52.4645.

PMID:
24395857
15.
16.

What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination.

Lynge E, Antilla A, Arbyn M, Segnan N, Ronco G.

Eur J Cancer. 2009 Oct;45(15):2714-21. doi: 10.1016/j.ejca.2009.07.024. Review.

PMID:
19695870
17.

Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.

Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, Barry M.

Vaccine. 2008 Oct 16;26(44):5654-61. doi: 10.1016/j.vaccine.2008.07.098.

PMID:
18723068
18.

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.

Castellsagué X, Schneider A, Kaufmann AM, Bosch FX.

Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23. doi: 10.1016/j.ygyno.2009.09.021.

PMID:
19819540
19.

Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.

Gunasekaran B, Jayasinghe Y, Brotherton JM, Fenner Y, Moore EE, Wark JD, Fletcher A, Tabrizi SN, Garland SM.

Vaccine. 2015 Feb 4;33(6):826-31. doi: 10.1016/j.vaccine.2014.11.002.

PMID:
25444782
20.

Supplemental Content

Support Center